Early results show two drugs may be better than one to treat most deadly skin cancer

February 12, 2013, Cancer Research UK
Early results show two drugs may be better than one to treat most deadly skin cancer

Adding lung cancer drugs to targeted melanoma treatment could increase survival for certain patients, according to research published in Cancer Discovery today.

Scientists at Cancer Research UK's Paterson Institute at The University of Manchester showed that lung such as (Iressa) can override resistance to new targeted therapies for , called BRAF inhibitors.

The first BRAF inhibitor, vemurafenib (Zelboraf), was approved for patients on the NHS in 2012, and others are currently in development. They work by targeting a faulty version of the BRAF protein, found in more than half of all melanomas as well as some other .

But patients often become resistant to BRAF inhibitors after a short time and their disease returns, leaving them without further treatment options.

Now scientists have found that treating BRAF inhibitor- or tumours with the drugs gefitinib or dasatinib, which block a different biological pathway, can halt their growth.

Lead author, Professor Richard Marais, director of Cancer Research UK's Paterson Institute, said: "This exciting research shows that two drugs can be better than one in beating this deadly disease.

"If these findings are confirmed in larger studies, combining two drug types could provide an effective new treatment for skin cancer patients for whom the only existing targeted treatment available – vermurafenib – no longer works.  

"This is a vital step to understand how to treat the disease more effectively but there is still a lot to do. We hope that this work accelerates progress that will ultimately increase survival from ."

Around 12,800 people in the UK are diagnosed with each year and there are around 2,200 deaths from the disease.

Dr Julie Sharp, Cancer Research UK's senior science information manager, said: "These new results builds on our work on the BRAF gene, which has led to the development of important new drugs for melanoma.  

"This fundamental research into the biology of cancer is leading directly to new treatments and we hope that this latest study will bring forward more effective approaches for treating melanoma, which we urgently need. This is the kind of work that the new Manchester Cancer Research Centre excels at - bringing together a wide range of expertise to revolutionise cancer treatment."

Explore further: New drug, Vemurafenib, doubles survival of metastatic melanoma patients

More information: Girotti, M. et al. Inhibiting EGF receptor or SRC family kinase signalling overcomes BRAF inhibitor resistance in melanoma, Cancer Discovery.

Related Stories

New drug, Vemurafenib, doubles survival of metastatic melanoma patients

March 1, 2012
A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib – increasing median survival ...

Study suggests patients should be screened before receiving vemurafenib

August 14, 2012
Different genetic mistakes driving skin cancer may affect how patients respond to the drug vemurafenib, providing grounds to screen people with melanoma skin cancer before treatment, a new study by Cancer Research UK scientists ...

Diabetes treatment doubles skin cancer drug's effectiveness

April 2, 2012
Combining the experimental drug Avastin (bevacizumab) with the diabetes drug Metformin almost doubles its ability to reduce skin cancer growth, according to a study in Cancer Discovery.

Second mutation in BRAF-mutated melanoma doesn't contribute to resistance

April 1, 2012
A second mutation found in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what scientists expected to be true.

Study uncovers mechanism by which melanoma drug accelerates secondary skin cancers

January 18, 2012
Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer. Now, researchers at UCLA's ...

Recommended for you

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.